Ventilator associated pneumonia in the ICU: Where has it gone?

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 3, 2015, Pages 226-231

  Guillamet, Cristina Vazquez ^a   Kollef, Marin H ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Outcomes; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM IDENTIFICATION; BLOOD SAMPLING; CRITICALLY ILL PATIENT; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MASS FRAGMENTOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PSEUDOMONAS AERUGINOSA; REVIEW; VENTILATED PATIENT; VENTILATOR ASSOCIATED PNEUMONIA; MICROBIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; STATISTICS AND NUMERICAL DATA;

HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84926310915     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000151     Document Type: Review

References (65)

1. Kollef MH, Chastre J, Fagon JY, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med 2014; 42:2178-2187.
2. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia ina large USdatabase. Chest 2002; 122:2115-2121.
3. Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 2011; 184:1133-1139.
4. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomized prevention studies. Lancet Infect Dis 2013; 13:665-671.
5. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012; 33:250-256.
6. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268.
7. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 2008; 23:91-100.
8. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362.
9. Grgurich PE, Hudcova J, Lei Y, et al. Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med 2012; 6:533-555.
10. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
11. Klompas M. What can we learn from international ventilator-associated pneumonia rates? Crit Care Med 2012; 40:3303-3304.
12. European Center for Disease Prevention and Control. Annual epidemiological report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC; 2011.
13. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med 2012; 40:281-284.
14. Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events. Crit Care Med 2013; 41:2467-2475.
15. Enne VI, Personne Y, Grgic L, et al. Aetiologyofhospital-acquiredpneumoniaand trends in antimicrobial resistance. Curr Opin Pulm Med 2014; 20:252-258.
16. Muscedere J, Sinuff T, Heyland DK, et al. The clinical impact and preventability of ventilator-associated conditions in critically ill patients who are mechanically ventilated. Chest 2013; 144:1453-1460.
17. Boyer AF, Schoenberg N, Babcock H, et al. A prospective evaluation of ventilator-associated conditions and infection-related ventilator-associated conditions. Chest 2015; 147:68-81.
18. Klein Klouwenberg PM, van Mourik MS, Ong DS, et al. Electronic implemen-tation of a novel surveillance paradigm for ventilator-associated events. Feasibility and validation. Am J Respir Crit Care Med 2014; 189:947-955.
19. Lilly CM, Landry KE, Sood RN, et al. Prevalence and test characteristics of national health safety network ventilator-associated events. Crit Care Med 2014; 42:2019-2028.
20. Carbonnelle E, Beretti JL, Cottyn S, et al. Rapid identification of Staphylococci isolated in clinical microbiology laboratories by matrix-assisted laser deso-rption ionization-time of flight mass spectrometry. J Clin Microbiol 2007; 45:2156-2161.
21. Mellmann A, Bimet F, Bizet C, et al. High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J Clin Microbiol 2009; 47:3732-3734.
22. Burnham CA, Frobel RA, Herrera ML, Wickes BL. Rapid ertapenem susceptibility testing and Klebsiella pneumoniae carbapenemase phenotype detec tion in Klebsiella pneumoniae isolates by use of automated microscopy of immobilized live bacterial cells. J Clin Microbiol 2014; 52:982-986.
23. Wallace M, Hance H, Michel C, Burnham CD. Rapid Identification of gramnegative bacteria in positive blood culture broth using a multiplex fluores cence in situ hybridization (FISH) assay and automated microscopy. 2014; ICAAC Poster Book. ICAAC 2014, Poster D-873. Washington, DC.
24. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
25. Trevino S, Pence M, Marschall J, et al. MRSA PCR on respiratory specimens from ventilated patients with suspected pneumonia: a potential tool for antimicrobial stewardship. 2014; Poster session presented at: ID week, Philadelphia, PA; 8-12 October.
26. May A, Brady J, Romano-Keeler J, Drake W, et al. A pilot study of noninvasive assessment of the lung microbiota as a potential tool for the early diagnosis of ventilator-associated pneumonia. Chest 2014; doi: 10.1378/chest.14-1687. [Epub ahead of print]
27. Dutta R, Hines EL, Gardner JW, Boilot P. Bacteria classification using Cyranose 320 electronic nose. Biomed Eng Online 2002; 1:4.
28. Vazquez Guillamet C, Leen J, Hsu J. Bacterial pathogen identification by volatile organic compounds in gas samples using optical spectrum technology (mid-infrared incoherent cavity ring down spectroscopy). San Francisco, CA; 2012: Poster session presented at: American Thoracic Society International Conference, 18-23 May.
29. Hanson CW, Thaler ER. Electronic nose prediction of a clinical pneumonia score: biosensors and microbes. Anesthesiology 2005; 102:63-68.
30. Bos LD, Martin-Loeches I, Kastelijn JB, et al. The volatile metabolic fingerprint of ventilator-associated pneumonia. Intensive Care Med 2014; 40:761-762.
31. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394.
32. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs. Vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797.
33. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-629.
34. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Sta-phylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356-1362.
35. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Sta-phylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732-2738.
36. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
37. Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030-2037.
38. Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother 2015; 70:624-625.
39. Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014; 58:2541-2546.
40. Tattevin P, Boutoille D, Vitrat V, et al. Salvage treatment of methicillin-resistant Staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 2014; 69:2010-2013.
41. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. Aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the 'seesaw effect'. Antimicrob Agents Chemother 2013; 57:2664-2668.
42. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 2014; 58:672-677.
43. Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized doubleblind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59:51-61.
44. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-asso ciated pneumonia. Crit Care Med 2008; 36:737-744.
45. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35:1888-1895.
46. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-1172.
47. McGovern PC, Wible M, El-Tahtawy A, et al. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 2013; 41:463-467.
48. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-1709.
49. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140-151.
50. Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipe-nem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57:1756-1762.
51. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218.
52. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41:489-495.
53. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071-2078.
54. Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:581-589.
55. Chant C, Leung A, Friedrich JO. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Crit Care 2013; 17:R279.
56. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236-244.
57. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-2598.
58. Capellier G, Mockly H, Charpentier C, et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One 2012; 7:e41290.
59. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short-vs. Long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144:1759-1767.
60. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2011; 10:CD007577.
61. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34:1364-1375.
62. Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014; 190:1102-1110.
63. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32-40.
64. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343-1348.
65. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115.